How I treat How I treat plasma cell leukemia
نویسندگان
چکیده
Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell proliferative disorder with a very poor prognosis and with distinct biologic, clinical, and laboratory features. Compared with multiple myeloma, pPCL presents more often with extramedullary involvement, anemia, thrombocytopenia, hypercalcemia, elevated serum 2-microglobulin and lactate dehydrogenase levels, as well as impaired renal function. Many of the genetic aberrations observed in newly diagnosed pPCL are typically found in advanced multiple myeloma. These cytogenetic abnormalities and mutations lead to increased proliferation, enhanced inhibition of apoptosis, escape from immune surveillance, and independence from the BM microenvironment, with changes in expression of adhesion molecules or chemokine receptors. The outcome of pPCL has improved with the introduction of autologous stem cell transplantation and combination approaches with novel agents, including bortezomib and immunomodulatory drugs, such as lenalidomide. In this review, we provide an overview of currently available therapeutic options with recommendations of how these treatment modalities can best be used to improve outcome for plasma cell leukemia patients. (Blood. 2012;120(12): 2376-2389)
منابع مشابه
How I Treat How I treat leukemia during pregnancy
http://bloodjournal.hematologylibrary.org/content/123/7/974.full.html Updated information and services can be found at: (1146 articles) Myeloid Neoplasia (123 articles) How I Treat (2303 articles) Free Research Articles Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about r...
متن کاملHow I treat relapsed childhood acute lymphoblastic leukemia Short Title: Treatment of relapsed ALL in childhood
متن کامل
How I treat How I treat acute myeloid leukemia
More than one quarter of a million adults throughout the world are diagnosed annually with acute myeloid leukemia (AML). Despite considerable progress during the past 3 decades in the therapy of AML, two-thirds of young adults and 90% of older adults still die of their disease. The reported median age has increased over the past few decades, mostly because of a greater willingness of physicians...
متن کاملHow I treat How I treat relapsed childhood acute lymphoblastic leukemia
The most common cause of treatment failure in childhood acute lymphoblastic leukemia (ALL) remains relapse, occurring in 15%-20% of patients. Survival of relapsed patients can be predicted by site of relapse, length of first complete remission, and immunophenotype of relapsed ALL. BM and early relapse (< 30 months from diagnosis), as well as T-ALL, are associated with worse prognosis than isola...
متن کاملHow I treat How I treat pediatric acute myeloid leukemia
Acute myeloid leukemia is a heterogeneous disease that accounts for approximately 20% of acute leukemias in children and adolescents. Despite the lack of targeted therapy for most subtypes and a dearth of new agents, survival rates have reached approximately 60% for children treated on clinical trials in developed countries. Most of the advances have been accomplished by better risk classificat...
متن کامل